Protocol Ledger

NCT03781414 · Phase II · TERMINATED

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extensio

Interventional Phase II clinical trial protocol NCT03781414 sponsored by Novartis in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-07 Enrollment: 129 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03781414
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)129 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03781414
Protocol FieldVerified Registry Value
NCT IdentifierNCT03781414
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment129 participants (ACTUAL)
Registered Start Date2019-10-07
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI